Moderna Inc Biotechnology stock longs 2020

Moderna Biotechnology (mRNA) is a clinical-stage biotechnology company that develops therapeutics and vaccines based on messenger RNA for treating infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019, the company had 11 clinical trials programs and 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, systemic intracellular therapeutics.

Moderna Biotechnology (MRNA) stock forecast

Everyone is talking about brand-new stocks in the biotechnology industry. Moderna Biotech is a new stock that had an IPO last December 2018. It’s only one year and a few months old. Supply and demand is the force that governs the financial markets and our daily lives. Moderna Biotech (MRNA) is not an exception.

Moderna Biotech could be one company that develops a cure and vaccine for the new coronavirus. The outlook for healthcare companies has become murkier as fears over the novel coronavirus epidemic loom over the market. If the local epidemics in China and other countries spread and become a pandemic in the coming weeks, healthcare companies will be on the front line and could become good assets to own long term.

Let’s have a look at the weekly timeframe. As you can see below, we have a strong bullish impulse created around 19-20$ per share. We are interested in buying this biotechnology stock if it ever retraces down there and the stock is still in a clear uptrend.

The big story in biotechnology this past week has been the rise and fall of the share prices of Gilead Sciences and the stock we are analysing in this post, Moderna (mRNA). These two companies have drawn a lot of attention for their progress on treatment and a vaccine for the coronavirus.

We can see how the supply and demand technical analysis on Moderna Biotechnology tells us there is a huge imbalance in the weekly timeframe. That’s all we need to know, a huge imbalance where to buy the underlying biotech stock if it ever retraces down there.

The new drugs seem promising; the supply and demand stock analysis show exactly that. This is the kind of stock technical analysis we should perform on every stock.